Hesca-2, a monoclonal antibody (mAb) IgM raised to the human embryonic stem cell (hESC) line BG-01v, binds with high affinity (nM) to the disaccharide epitope (Galβ1-3GlcNAc) on a glycan microarray. This epitope was expressed on pluripotent progenitor hESCs in culture, but not in various differentiated cells derived from hESC based on immunofluorescence microscopy. Hesca-2 stains a limited subset of cells in adult human tissues (eg, esophagus and breast). This mAb also crossreacts in immunofluorescence microscopy studies with several human ovarian cancer cell lines and is cytotoxic to them based on the release of cytosolic enzyme lactate dehydrogenase into the media. Hesca-2 immunohistochemically stained tissue from a number of human tumors, including ovary, breast, colon, and esophageal cancer. These data suggest that Hesca-2 recognizes a surface marker found both in stem cells and certain cancer cells.
Get full access to this article
View all access options for this article.
References
1.
HendersonJK, DraperJS, BaillieHS, FishelS, ThomsonJA, MooreH, AndrewsPW. 2002. Preimplantation human embryos and embryonic stem cells show comparable expression of stage-specific embryonic antigens. Stem Cells, 20:329–337.
2.
CarpenterMK, RoslerE, RaoMS. 2003. Characterization and differentiation of human embryonic stem cells. Cloning Stem Cells, 5:79–88.
3.
ZengX, MiuraT, LuoY, BhattacharyaB, CondieB, ChenJ, GinisI, LyonsI, MejidoJ, PuriRK, RaoMS, FreedWJ. 2004. Properties of pluripotent human embryonic stem cells BG01 and BG02. Stem Cells, 22:292–312.
4.
BadcockG, PigottC, GoepelJ, AndrewsPW. 1999. The human embryonal carcinoma marker antigen TRA-1-60 is a sialylated keratan sulfate proteoglycan. Cancer Res, 59:4715–4719.
5.
BrimbleSN, SherrerES, UhlEW, WangE, KellyS, MerrillAHJr., RobinsAJ, SchulzTC. 2007. The cell surface glycosphingolipids SSEA-3 and SSEA-4 are not essential for human ESC pluripotency. Stem Cells, 25:54–62.
6.
PrzyborskiSA. 2001. Isolation of human embryonal carcinoma stem cells by immunomagnetic sorting. Stem Cells, 19:500–504.
7.
SidhuKS, TuchBE. 2006. Derivation of three clones from human embryonic stem cell lines by FACS sorting and their characterization. Stem Cells Dev, 15:61–69.
8.
FerrandinaG, BonannoG, PierelliL, PerilloA, ProcoliA, MariottiA, CoralloM, MartinelliE, RutellaS, PagliaA, ZannoniG, MancusoS, ScambiaG. 2007. Expression of CD133-1 and CD133-2 in ovarian cancer. Int J Gynecol Cancer, 18:506–514.
KusumbeAP, MaliAM, BapatSA. 2009. CD133-expressing stem cells associated with ovarian metastases establish an endothelial hierarchy and contribute to tumor vasculature. Stem Cells, 27:498–508.
11.
BonfantiL. 2006. PSA-NCAM in mammalian structural plasticity and neurogenesis. Prog Neurobiol, 80:129–164.
12.
GasconE, VutskitsL, KissJZ. 2007. Polysialic acid-neural cell adhesion molecule in brain plasticity: from synapses to integration of new neurons. Brain Res Rev, 56:101–118.
13.
PlaiaTW, JosephsonR, LiuY, ZengX, OrdingC, ToumadjeA, BrimbleSN, SherrerES, UhlEW, FreedWJ, SchulzTC, MaitraA, RaoMS, AuerbachJM. 2006. Characterization of a new NIH-registered variant human embryonic stem cell line, BG01V: a tool for human embryonic stem cell research. Stem Cells, 24:531–546.
HarlowE, LaneD. 1998. Using Antibodies. A Laboratory Manual. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, 495.
16.
PricePW, McKinneyEC, WangY, SasserLE, KandasamyMK, MatsuuchiL, MilcarekC, DealRB, CulverDG, MeagherRB. 2009. Engineered cell surface expression of membrane immunoglobulin as a means to identify monoclonal antibody-secreting hybridomas. J Immunol Methods, 343:28–41.
17.
GildersleeveJC, OyelaranO, SimpsonJT, AllredB. 2008. Improved procedure for direct coupling of carbohydrates to proteins via reductive amination. Bioconjugate Chem, 19:1485–1490.
18.
OyelaranOO, LiQ, FarnsworthDF, GildersleeveJC. 2009. Microarrays with varying carbohydrate density reveal distinct subpopulations of serum antibodies. J Proteome Res, 8:3529–3538.
19.
OyelaranO, McShaneLM, DoddL, GildersleeveJC. 2009. Profiling human serum antibodies with a carbohydrate antigen microarray. J Proteome Res, 8:4301–4310.
20.
SongEH, PohlNLB. 2009. Carbohydrate arrays: recent developments in fabrication and detection methods with applications. Curr Opin Chem Biol, 13:626–632.
JonesRB, GordusA, KrallJA, MacBeathG. 2006. A quantitative protein interaction network for the ErbB receptors using protein microarrays. Nature, 439:168–174.
24.
KobataA, GinsburgV. 1972. Oligosaccharides of human milk. 3. Isolation and characterization of a new hexasaccharide, lacto-N-hexaose. J Biol Chem, 247:1525–1529.
25.
YamashitaK, TachibanaY, KobataA. 1977. Oligosaccharides of human milk:structures of three lacto-N-hexaose derivatives with H-haptenic structure. Arch Biochem Biophys, 182:546–555.
26.
DuaVK, GosoK, DubeVE, BushCA. 1985. Characterization of lacto-N-hexaose and two fucosylated derivatives from human milk by high-performance liquid chromatography and proton NMR spectroscopy. J Chromatogr, 328:259–269.
27.
LooD, PryerN, YoungP, LiangT, CoberlyS, KingKL, KangK, RobertsP, TsaoM, XuX, PottsB, MatherJP. 2007. The glycotope-specific RAV12 monoclonal antibody induces oncosis in vitro and has antitumor activity against gastrointestinal adenocarcinoma tumor xenografts in vivo. Mol Cancer Ther, 6:856–865.
28.
CoberlySK, ChenFZ, ArmaniniMP, ChenY, YoungPF, MatherJP, LooDT. 2009. The RAV12 monoclonal antibody recognizes the N-linked glycotope RAAG12: expression in human normal and tumor tissues. Arch Pathol Lab Med, 133:1403–1412.
29.
RettigWJ, Cordon-CardoC, NgJS, OettgenHF, OldLJ, LloydKO. 1985. High-molecular-weight glycoproteins of human teratocarcinoma defined by monoclonal antibodies to carbohydrate determinants. Cancer Res, 45:815–821.
30.
GooiHC, WilliamsLK, UemuraK, HounsellEF, McIlhinneyRA, FeiziT. 1983. A marker of human foetal endoderm defined by a monoclonal antibody involves type 1 blood group chains. Mol Immunol, 20:607–613.
31.
WilliamsLK, SullivanA, McIlhinneyRA, NevilleAM. 1982. A monoclonal antibody marker of human primitive endoderm. Int J Cancer, 30:731–738.
32.
OhbayashiH, EndoT, YamashitaK, KurokiM, MatsuokaY, KobataA. 1989. Novel methods to determine the epitopes on the asparagine-linked oligosaccharides of glycoproteins. Anal Biochem, 182:200–206.
33.
KabatEA, LiaoJ, ShyongJ, OssermanEF. 1982. A monoclonal IgM lambda macroglobulin with specificity for lacto-N-tetraose in a patient with bronchogenic carcinoma. J Immunol, 128:540–544.
34.
NozawaS, NarisawaS, KojimaK, SakayoriM, IizukaR, MochizukiH, YamauchiT, IwamoriM, NagaiY. 1989. Human monoclonal antibody (HMST-1) against lacto-series type 1 chain and expression of the chain in uterine endometrial cancers. Cancer Res, 49:6401–6406.
35.
LanctotPA, GageFH, VarkiAP. 2007. The glycans of stem cells. Curr Opin Chem Biol, 11:373–380.
36.
HeiskanenA, HirvonenT, SaloH, ImpolaU, OlonenA, LaitinenA, TiitinenS, NatunenS, AitioO, Miller-PodrazaH, WuhrerM, DeelderAM, NatunenJ, LaineJ, LehenkariP, SaarinenJ, SatomaaT, ValmuL. 2009. Glycomics of bone marrow-derived mesenchymal stem cells can be used to evaluate their cellular differentiation stage. Glycoconj J, 26:367–384.
37.
SatomaaT, HeiskanenA, MikkolaM, OlssonC, BlomqvistM, TiittanenM, JaatinenT, AitioO, OlonenA, HelinJ, HiltunenJ, NatunenJ, TuuriT, OtonkoskiT, SaarinenJ, LaineJ. 2009. The N-glycome of human embryonic stem cells. BMC Cell Biol, 2:10:42.
38.
SellS. 2004. Stem cell origin of cancer and differentiation therapy. Crit Rev Oncol Hematol, 51:1–28.
39.
SoltysovaA, AltanarovaV, AltanerC. 2005. Cancer stem cells. Neoplasma, 52:435–440.
40.
Martinez-ClementJA, AndreuEJ, ProsperF. 2006. Somatic stem cells and the origin of cancer. Clin Transl Oncol, 8:647–663.
41.
BertoliniG, RozL, PeregoP, TortoretoM, FontanellaE, GattiL, PratesiG, FabbriA, AndrianiF, TinelliS, RozE, CaseriniR, VulloLo S, CameriniT, MarianiL, DeliaD, CalabròE, PastorinoU, SozziG. 2009. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci U S A, 106:16281–16286.
42.
BuessM, RajskiM, Vogel-DurrerBML, HerrmannR, RochlitzC. 2009. Tumor-endothelial interaction links the CD44+/CD24− phenotype with poor prognosis in early-stage breast cancer. Neoplasia, 11:987–1002.
43.
SinghS, ClarkeID, HideT, DirksPB. 2004. Cancer stem cells in nervous system tumors. Oncogene, 23:7267–7273.
44.
BidlingmaierS, ZhuX, LiuB. 2008. The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells. J Mol Med, 86:1025–1032.
45.
WrightMH, CalcagnoAM, SalcidoCD, CarlsonMD, AmbudkarSV, VarticovskiL. 2008. Brca1 breast tumors contain distinct CD44+/CD24− and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res, 10:R10.
46.
YangRY, RabinovichGA, LiuFT. 2008. Galectins: structure, function and therapeutic potential. Expert Rev Mol Med, 10:e17.
47.
RabinovichGA, ToscanoMA. 2009. Turning “sweet” on immunity: galectin-glycan interactions in immune tolerance and inflammation. Nat Rev Immunol, 9:338–352.
48.
Consortium for Functional Glycomics (CFG)www.functionalglycomics.org/glycomics/publicdata/primaryscreen.jsp
49.
SaussezS, DecaesteckerC, CludtsS, ErnouxP, ChevalierD, SmetanaKJr., AndréS, LeroyX, GabiusHJ. 2009. Adhesion/growth-regulatory tissue lectin galectin-1 in relation to angiogenesis/lymphocyte infiltration and prognostic relevance of stromal up-regulation in laryngeal carcinomas. Anticancer Res, 29:59–65.
50.
ChanJ, O'DonoghueK, GavinaM, TorrenteY, KenneaN, MehmetH, StewartH, WattDJ, MorganJE, FiskNM. 2006. Galectin-1 induces skeletal muscle differentiation in human fetal mesenchymal stem cells and increases muscle regeneration. Stem Cells, 24:1879–1891.
51.
SakaguchiM, ShingoT, ShimazakiT, OkanoHJ, ShiwaM, IshibashiS, OguroH, NinomiyaM, KadoyaT, HorieH, ShibuyaA, MizusawaH, PoirierF, NakauchiH, SawamotoK, OkanoH. 2006. A carbohydrate-binding protein, galectin-1, promotes proliferation of adult neural stem cells. Proc Natl Acad Sci U S A, 103:7112–7117.
52.
LeeMY, LeeSH, ParkJH, HanHJ. 2009. Interaction of galectin-1 with caveolae induces mouse embryonic stem cell proliferation through the Src, ERas, Akt and mTOR signaling pathways. Cell Mol Life Sci, 66:1467–1478.
53.
VasV, Fajka-BojaR, IonG, DudicsV, MonostoriE, UherF. 2005. Biphasic effect of recombinant galectin-1 on the growth and death of early hematopoietic cells. Stem Cells, 23:279–287.
FriedrichsJ, ManninenA, MullerDJ, HeleniusJ. 2008. Galectin-3 regulates integrin alpha2beta1-mediated adhesion to collagen-I and -IV. J Biol Chem, 283:32264–32272.
56.
SaravananC, LiuFT, GipsonIK, PanjwaniN. 2009. Galectin-3 promotes lamellipodia formation in epithelial cells by interacting with complex N-glycans on alpha3beta1 integrin. J Cell Sci, 15,122(Pt20):3684–3693.
57.
NakaharaS, RazA. 2008. Biological modulation by lectins and their ligands in tumor progression and metastasis. Anticancer Agents Med Chem, 8:22–36.
58.
SaussezS, KissR. 2006. Galectin-7. Cell Mol Life Sci, 63:686–697.
59.
LajoieP, GoetzJG, DennisJW, NabiIR. 2009. Lattices, rafts, and scaffolds: domain regulation of receptor signaling at the plasma membrane. J Cell Biol, 185:381–385.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
